Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The other above-mentioned global SURMOUNT studies are still ongoing, in SURMOUNT-2, 938 participants with T2D are enrolled receiving either 10 or 15 mg of tirzepatide
The American Diabetes Association (ADA) recommends these medications in patients with T2D and ASCVD, chronic kidney disease (CKD), and/or HF, independent of glycemic control or metformin use [1]
Additional benefits have been observed in renal outcomes , with some GLP-1 agonists showing protective effects, primarily through reductions in albuminuria and a slower decline in estimated glomerular filtration rate (eGFR)
This FREE sample will include data analysis, ranging from market trends to estimates and forecasts
